| Literature DB >> 36259044 |
Reenu Kashyap1, Kapil Singh Narayan2, Shilpa Vij1.
Abstract
Colostrum known as "liquid gold" contains approximately 60-80% of whey proteins that can be a great source of bioactive peptide production. Therefore, this study aimed to perform a comparative antimicrobial evaluation of the bioactive peptide generated from L. rhamnosus C25, L. rhamnosus C6, and L. casei NCDC17 fermented colostrum whey. Peptide fractions 10 kDa, 5 kDa, and 3 kDa were isolated using their respective molecular weight cut-off membranes and antimicrobial activity was evaluated against diarrheagenic E. coli strains. The higher inhibition was shown by < 10 kDa peptide fractions from L. rhamnosus C25 fermented colostrum whey and the zone of inhibition was 15 ± 0.06 (E. coli MTCC 723), 17 ± 0.04 (E. coli MTCC 724), 18 ± 0.05 (E. coli MTCC 725), and 17 ± 0.02 (E. coli ATCC 25922). In addition, ST-1 and LT-1 genes of E. coli strains were also confirmed using PCR which is responsible for the diarrheagenic property. Further, the interaction of potent peptides against E. coli strains was also observed by scanning electron microscope. Hence, the significance of the present study emphasized that these bioactive peptides generated from fermented colostrum whey can be used as ingredients in functional food against diarrhoea. © Association of Food Scientists & Technologists (India) 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Entities:
Keywords: A bioactive peptide; Antimicrobial activity; Colostrum whey; Fermentation
Year: 2022 PMID: 36259044 PMCID: PMC9559551 DOI: 10.1007/s13197-022-05606-x
Source DB: PubMed Journal: J Food Sci Technol ISSN: 0022-1155 Impact factor: 3.117
Total peptide content present in the fractions obtained from fermented colostrum whey
| Peptide content (mg lysine/mL) | ||||||
|---|---|---|---|---|---|---|
| > 10 kDa | < 10 kDa | 5–10 kDa | < 5 kDa | 3–5 kDa | < 3 kDa | |
fermented whey | 8.1 ± 0.04b | 7.92 ± 0.01c | 7.32 ± 0.03d | 6.35 ± 0.03d | 5.32 ± 0.03d | 4.35 ± 0.03d |
fermented whey | 7.09 ± 0.04b | 6.55 ± 0.01c | 6.49 ± 0.03d | 6.45 ± 0.03d | 5.55 ± 0.03d | 4.52 ± 0.03d |
fermented whey | 6.09 ± 0.04b | 5.89 ± 0.01c | 5.02 ± 0.03d | 4.52 ± 0.03d | 4.02 ± 0.03d | 3.52 ± 0.03d |
Values are mean ± S.E.M. of triplicate
Values a, b, c, d are significantly different at P ≤ 0
L. rhamnosus C25, Lacticaseibacillus rhamnosus C25; L. rhamnosus C6, Lacticaseibacillus rhamnosus C6; L. casei NCDC17, Lacticaseibacillus casei NCDC17
Fig. 1Antimicrobial activity of bioactive peptide fraction obtained from a L. rhamnosus C25 fermented colostrum whey; b L. rhamnosus C6 fermented colostrum whey; c L. casei NCDC17 fermented colostrum whey against E. coli stains. d Plate represents antimicrobial activity of ultrafiltered fraction obtained from L. rhamnosus C25 fermented colostrum whey against E. coli MTCC 723. Values are mean ± S.E.M. of triplicate. Values a, b, c, d, e, f are significantly different at P ≤ 0.05. All zone of inhibition including 6 mm of well diameter*
Antimicrobial activity of bioactive peptide obtained after ultra-filtered fractions against diarrhoeagenic E. coli strains
| Peptide fractions obtained from | kDa | ||||
|---|---|---|---|---|---|
| > 10 | 13 ± 0.03b | 14 ± 0.03b | 14 ± 0.03b | 14 ± 0.03b | |
| < 10 | 15 ± 0.07c | 17 ± 0.07c | 18 ± 0.07c | 17 ± 0.07c | |
| 5–10 | 8 ± 0.03d | 9 ± 0.03d | 10 ± 0.03d | 9 ± 0.03d | |
| < 5 | 8.7 ± 0.07d | 10 ± 0.07e | 9.5 ± 0.07e | 10 ± 0.07e | |
| 3–5 | 6.5 ± 0.05e | 6.5 ± 0.05f | 7 ± 0.05f | 6.5 ± 0.05f | |
| < 3 | 6 ± 0.04e | 6 ± 0.04f | 6 ± 0.04f | 6 ± 0.04f | |
| > 10 | 8.4 ± 0.04b | 9 ± 0.04b | 9.5 ± 0.04b | 9.5 ± 0.04b | |
| < 10 | 11 ± 0.04b | 12 ± 0.04b | 13 ± 0.04b | 13 ± 0.04b | |
| 5–10 | 6.5 ± 0.05a | 7 ± 0.05a | 7.5 ± 0.05a | 6.9 ± 0.05a | |
| < 5 | 8 ± 0.04b | 7.5 ± 0.04b | 7.7 ± 0.04b | 8 ± 0.04b | |
| 3–5 | 6.4 ± 0.01c | 6.7 ± 0.01c | 7 ± 0.01c | 6.5 ± 0.01c | |
| < 3 | 6 ± 0.03d | 6 ± 0.03d | 6 ± 0.03d | 6 ± 0.03d | |
| > 10 | 6 ± 0.05a | 6 ± 0.05a | 8 ± 0.05a | 6 ± 0.05a | |
| < 10 | 6 ± 0.04b | 6.7 ± 0.04b | 7.5 ± 0.04b | 6 ± 0.04b | |
| 5–10 | 6 ± 0.01c | 6 ± 0.01c | 7 ± 0.01c | 6 ± 0.01c | |
| < 5 | 6 ± 0.03d | 6 ± 0.03d | 6 ± 0.03d | 6 ± 0.03d | |
| 3–5 | 6 ± 0.07e | 6 ± 0.07e | 6 ± 0.07e | 6 ± 0.07e | |
| < 3 | 6 ± 0.05a | 6 ± 0.05a | 6 ± 0.05a | 6 ± 0.05a |
Values are mean ± S.E.M. of triplicate
Values a, b, c, d,e are significantly different at P ≤ 0.05
All zone of inhibition including 6 mm of well diameter
L. rhamnosus C25, Lacticaseibacillus rhamnosus C25; L. rhamnosus C6, Lacticaseibacillus rhamnosus C6; L. casei NCDC17, Lacticaseibacillus casei NCDC17
MIC of the bioactive peptide with highest antimicrobial activity derived from colostrum whey fermented with L. rhamnosus C25 and L. rhamnosus C6
| IC50 (mg/ml) | |||||
|---|---|---|---|---|---|
| Peptide fractions obtained from | kDa | ||||
| > 10 | 2.12 ± 0.4a | 0.53 ± 0.3b | 0.13 ± 0.7c | 0.26 ± 0.3d | |
| < 10 | 0.49 ± 0.4a | 0.06 ± 0.1b | 0.03 ± 0.7c | 0.06 ± 0.003d | |
| 5–10 | 3.65 ± 0.6a | 0.91 ± 0.8b | 0.45 ± 0.3c | 0.91 ± 0.7d | |
| < 5 | 3.175 ± 0.9a | 0.79 ± 0.4b | 0.39 ± 0.1c | 0.79 ± 0.3d | |
| > 10 | 1.86 ± 0.5a | 0.46 ± 0.4b | 0.23 ± 0.1c | 0.46 ± 0.3d | |
| < 10 | 0.81 ± 0.5a | 0.20 ± 0.4b | 0.10 ± 0.1c | 0.20 ± 0.3d | |
| 5–10 | 3.75 ± 0.7a | 1.86 ± 0.3b | 0.931 ± 0.6c | 1.86 ± 0.8d | |
| < 5 | 3.26 ± 0.5a | 1.63 ± 0.6b | 1.63 ± 0.2c | 1.63 ± 0.3d | |
Values are mean ± S.E.M. of triplicate
Values a, b, c, d are significantly different at P ≤ 0.05
L. rhamnosus C25, Lacticaseibacillus rhamnosus C25; L. rhamnosus C6, Lacticaseibacillus rhamnosus C6; L. casei NCDC17, Lacticaseibacillus casei NCDC17
Fig. 2Confirmation of a ST-1 at110 bp, b LT-1 gene at 154 bp in E. coli enterotoxigenic strains, where Lane 1 E. coli MTCC 723, Lane 2 E. coli MTCC 724, Lane 3 E. coli MTCC 725 and Lane 4 E. coli ATCC 25922. Lane 1 Marker, Lane 2 (E. coli MTCC 723, Lane 3 E. coli MTC 724, Lane 4 E. coli MTCC 724 and Lane 5 E. coli ATCC 25922
Fig. 3Scanning electron microscope view of antimicrobial activity against E. coli MTCC 723 a control, b E. coli MTCC 723 + < 10 kDa fraction, c E. coli MTCC 724 + < 10 kDa fraction, d E. coli MTCC 725 + < 10 kDa fraction, e E. coli ATCC 25922 + 10 kDa fraction